Key trials in ovarian cancer immunotherapy
| Study | Patients | Treatment | # of Patients | Response | Survival |
|---|---|---|---|---|---|
| Vald, Edwards Cancer Immunol Immunother 2010 | Recurrent, platinum resistant ovarian cancer | Interleukin-2 i.p. | 24 | CR: 4 | Median Survival: |
| 6 × 105 IU/ml weekly × 16 | PR: 2 | Non-Responder: | |||
| SD: 7 | 1.5 years | ||||
| Responders: not reached | |||||
| (24 -120+ months) | |||||
| Hodi, Dranoff | Recurrent metastatic ovarian cancer | CTLA-4 Blockade: | 9 | CR: 0 | Duration of Response: |
| PNAS 2008 | Ipilupimab i.v. 3 mg/kg q 2 – 3 months | PR: 1 | SD: 2,4,6+ Months | ||
| SD: 3 | PR: 35+ Months | ||||
| Diefenbach, Dupont | “High Risk” ovarian cancer after surgery and 1st line chemo | NY-ESO-1b peptide (position 157–165; 100 μg) + 0.5 mL Montanide ISA-51 s.c. q 3 weeks × 5 | 9 | NA | Median PFS: 13 months |
| Clin Cancer Res 2008 | 6/9 patients recurred | ||||
| 3 patient disease free after 25, 38, and 52 | |||||
| Fujita,Tanaka Clin Cancer Research 1995 | NED after surgery and 1st line chemo | 1.0 – 4.4 × 109 TIL after 1st line chemo | 13 TIL | NA | 3-year DFS: |
| 11 Control | TIL: 82.1% | ||||
| Control: 54.5% | |||||
| 3-year DFS, residual disease after surgery | |||||
| TIL: 76.2% | |||||
| Control: 33.3% | |||||
| Chu, June | Consolidation after 1st line treatment or secondary debulking | Her-2/neu, hTERT, PADRE-loaded Dendritic cells +/− Cyclophosphamide | 11 | NA | 5 recurrences |
| Cancer Immunol Immunother 2012 | 6 patients NED at 36 months | ||||
| 3-year OS 90% | |||||
| Odunsi, Jaeger | Consolidation after 1st line treatment | I.d. rV-NY-ESO-1, | 22 | NA | PFS: 21 months |
| PNAS 2012 | 3.1 × 107 PFU, monthly s.c. | OS: 48 months | |||
| rF-NY-ESO-1, 7.41 × 107 PFU for 6 mo. | |||||
| Rahma, Khleif | HLA-A2.1 + stage III, IV, or recurrent ovarian | Arm A: s.c. wt p53:264–272 peptide with Montanide and GM-CSF. | 21 | NA | Arm A: |
| Cancer Immunol Immunother 2012 | Immune responses 9/13 patients (69%), PFS: 4.2 months | ||||
| Cancer over-expressing the p53 protein, no evidence of disease | Arm B: i.v. wt p53:264–272 peptide-pulsed dendritic cells IV | OS: 40.8 months | |||
| IL-2 in both cohorts | Arm B: | ||||
| Immune responses 5/6 patients (83%) | |||||
| PFS: 8.7 months | |||||
| OS: 29.6 months |
Adapted from: Kandalaft LE, Powell DJ Jr, Singh N, Coukos G. Immunotherapy for ovarian cancer: what’s next? J Clin Oncol. 2011 Mar 1;29(7):925–33.